(117 days)
Not Found
No
The device description and performance studies focus on laser technology and clinical outcomes, with no mention of AI or ML.
Yes
The device is indicated for the "treatment of acne scars and wrinkles" and "tattoo and benign pigmented lesions removal," which are therapeutic applications.
No
The device is indicated for tattoo and benign pigmented lesions removal, and treatment of acne scars and wrinkles. It is a therapeutic device, not a diagnostic one.
No
The device description clearly states it is a "high-powered, Alexandrite system that delivers laser energy," indicating it is a hardware-based laser system, not software only.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is for tattoo and benign pigmented lesion removal, and treatment of acne scars and wrinkles. These are all procedures performed directly on the patient's body.
- Device Description: The device is a laser system that delivers energy to the skin. This is a therapeutic device, not a diagnostic one.
- Lack of IVD Characteristics: There is no mention of analyzing samples (blood, tissue, etc.) or providing diagnostic information about a patient's health condition. The device's function is to treat conditions, not diagnose them.
IVD devices are used to examine specimens derived from the human body to provide information for diagnostic, monitoring, or compatibility purposes. This device does not fit that description.
N/A
Intended Use / Indications for Use
755 nm:
The PicoSure workstation is indicated for tattoo and benign pigmented lesions removal. The PicoSure workstation with the 3mm and 6mm hand pieces and the Focus Array are indicated for the treatment of acne scars and wrinkles in Skin Types I-IV.
532 nm:
The PicoSure 532 nm Laser Delivery System is indicated for tattoo removal in Skin Types I-III.
Product codes (comma separated list FDA assigned to the subject device)
GEX
Device Description
The PicoSure™ workstation is a high-powered, Alexandrite system that delivers laser energy in the 755-nm nominal wavelength. The system offers fast and efficient treatment through a variety of spot sizes, fluences and repetition rates. Laser activation is by footswitch. In addition to the 755 nm handpiece, an optional 532 nm Laser Delivery System can replace the 755 nm handpiece at the distal end of the articulated arm. This 532 nm Laser Delivery System converts the 755 nm laser energy into a 532 nm wavelength and is available in multiple spot sizes.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Clinical tests submitted: The study was performed using 18 subjects with a total of 23 tattoos. Subjects were ages 24 - 47. Subjects received 2 to 7 treatments every 6 weeks (+/- 2 weeks). Subjects were divided into two groups and treated exclusively with PicoSure or the tattoo was split into two treatment areas and treated with PicoSure and the predicate device. Three blinded reviewers performed an evaluation of photographs using a 6 point categorical efficacy scoring scale as well as rating the clearance of individual colors present in the tattoo. Mean scores for all three evaluators were calculated per subject to determine overall mean scores. The results of the blinded evaluation were subjects treated with PicoSure were rated 3.8/6 overall mean score, showing the PicoSure to be as effective as the predicate device RevLite, rated 3.7/6 overall mean score. There were no deaths, serious adverse events (SAEs) or unanticipated adverse device effects (UADEs) reported in this study. The primary objectives of the study were to assess overall treatment efficacy through blinded photographic evaluation using a 6 point scale to grade improvement, assess safety of the PicoSure laser through the recording of side effects during the course of the study and compare efficacy of the PicoSure laser to the predicate device in a subset of patients, have been met.
Non-clinical tests submitted: Software verification and validation testing to support the 532 nm Laser Delivery System was successfully completed.
Conclusions drawn from clinical and non-clinical tests submitted: Testing confirmed that the PicoSure workstation with the 532 nm Laser Delivery System is safe and effective in the removal of tattoos.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
PicoSure Workstation K140719, RevLite Q-Switched Nd:YAG Laser System K133254
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 878.4810 Laser surgical instrument for use in general and plastic surgery and in dermatology.
(a)
Identification. (1) A carbon dioxide laser for use in general surgery and in dermatology is a laser device intended to cut, destroy, or remove tissue by light energy emitted by carbon dioxide.(2) An argon laser for use in dermatology is a laser device intended to destroy or coagulate tissue by light energy emitted by argon.
(b)
Classification. (1) Class II.(2) Class I for special laser gas mixtures used as a lasing medium for this class of lasers. The devices subject to this paragraph (b)(2) are exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 878.9.
0
Image /page/0/Picture/1 description: The image is a black and white logo for the U.S. Department of Health & Human Services. The logo features the department's name in a circular arrangement around a symbol. The symbol consists of three stylized human profiles facing right, with flowing lines representing hair or clothing.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
May 23, 2016
Cynosure, Inc. Ms. Kelli McMillan Regulatory Affairs Specialist 5 Carlisle Road. Westford, Massachusetts, 01886
Re: K143105
Trade/Device Name: Picosure™ Workstation with 532 nm Laser Delivery System Regulation Number: 21 CFR 878.4810 Regulation Name: Laser surgical instrument for use in general and plastic surgery and in dermatology Regulatory Class: Class II Product Code: GEX Dated: January 20, 2015 Received: January 21, 2015
Dear Ms. McMillan:
This letter corrects our substantially equivalent letter of February 23, 2015.
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. Isting of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21
1
CFR Part 807); labeling (21 CFR Part 801 ); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
Jennifer R. Stevenson -A
For Binita S. Ashar, M.D., M.B.A., F.A.C.S. Director Division of Surgical Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K141305
Device Name
Picosure™ Workstation with 532 nm Laser Delivery System
Indications for Use (Describe)
755 nm:
The PicoSure workstation is indicated for tattoo and benign pigmented lesions removal. The PicoSure workstation with the 3mm and 6mm hand pieces and the Focus Array are indicated for the treatment of acne scars and wrinkles in Skin Types I-IV.
532 nm:
The PicoSure 532 nm Laser Delivery System is indicated for tattoo removal in Skin Types I-III.
X Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
PicoSure™ Workstation 510(k) Summary K143105
| 807.92(a)(1) Submitter Information | |
|---|---|
| Applicant | Cynosure, Inc |
| Address | 5 Carlisle Road |
| Westford, MA 01886 | |
| Phone Number | (781) 993-2454 |
| Fax Number | (978) 256-6556 |
| Establishment Registration Number | 1222993 |
| Contact Person | Connie Hoy |
| Preparation Date | April 4, 2016 |
| 807.92(a)(2) Name of Device | |
| Trade or Proprietary Name | PicoSure Workstation with 532 nm Laser Delivery System |
| Common or Usual Name | Medical Laser System |
| Classification Name | Powered Laser Surgical Instrument |
| Classification Panel | General & Plastic Surgery |
| Regulation | 878.4810 |
| Product Code(s) | GEX |
| 807.92 (a)(3) Legally marketed device(s) to which equivalence is claimed | |
| PicoSure Workstation K140719 | |
| RevLite Q-Switched Nd:YAG Laser System K133254 | |
| 807.92(a){4) Device Description | |
| The PicoSure™ workstation is a high-powered, Alexandrite | |
| system that delivers laser energy in the 755-nm nominal | |
| wavelength. The system offers fast and efficient treatment | |
| through a variety of spot sizes, fluences and repetition rates. | |
| Laser activation is by footswitch. In addition to the 755 nm | |
| handpiece, an optional 532 nm Laser Delivery System can | |
| replace the 755 nm handpiece at the distal end of the | |
| articulated arm. This 532 nm Laser Delivery System | |
| converts the 755 nm laser energy into a 532 nm | |
| wavelength and is available in multiple spot sizes. | |
| 807.92(a)(5) Intended Use of the Device | |
| 755 nm: | |
| The PicoSure workstation is indicated for tattoo and benign | |
| pigmented lesions removal. The PicoSure workstation with the | |
| 3mm and 6mm handpieces and the Focus Array are indicated for | |
| the treatment of acne scars and wrinkles in Skin Types I-IV. | |
| 532 nm: | |
| The PicoSure 532 nm Laser Delivery System is indicated for | |
| tattoo removal. | |
| The modifications to the device have not changed the | |
| indications for use for the 755 nm wavelength. |
4
PicoSure™ Workstation
| 807.92(a)(6) Summary of the Technological Characteristics of the Device Compared to the Predicate | ||||
|---|---|---|---|---|
| Laser Type | PicoSure™ Workstation (KPending) Alexandrite | PicoSure Workstation (K140719) Alexandrite | RevLite (K133254) Nd:YAG | |
| Frequency doubled 1064 nm solid state laser | ||||
| Wavelength | 532 nm | 755 nm | 1064 nm/532 nm | |
| Maximum Average Fluence | 1.4 J/cm² | 6.37 J/cm² | 12 J/cm² @ 1064 nm | |
| 5 J/cm² @ 532 nm | ||||
| Repetition Rate | 1, 2.5, 5, 10 Hz | Single, 1, 2.5, 5, 10 Hz | Single shot, 1, 2, 5, 10 Hz | |
| Pulse Duration | 450ps-900 ps | 450ps-900ps | ≤ 20 ns | |
| Spot Sizes (mm) | Fixed 1.5-3.5 mm | Zoom 2-6 mm, Fixed 2, 3, 4, 6, 8, 10 mm | 2-8.5 mm, 0.1 mm increments | |
| 807.92(b)(1) Non-clinical tests submitted | Software verification and validation testing to support the 532 nm Laser Delivery System was successfully completed. | |||
| 807.92(b)(2) Clinical tests submitted | The study was performed using 18 subjects with a total of 23 tattoos. Subjects were ages 24 - 47. Subjects received 2 to 7 treatments every 6 | |||
| weeks (+/- 2 weeks). Subjects were divided into two groups and treated exclusively with PicoSure or the tattoo was split into two treatment | ||||
| areas and treated with PicoSure and the predicate device. Three blinded reviewers performed an evaluation of photographs using a 6 point | ||||
| categorical efficacy scoring scale as well as rating the clearance of individual colors present in the tattoo. Mean scores for all three evaluators | ||||
| were calculated per subject to determine overall mean scores. The results of the blinded evaluation were subjects treated with PicoSure were | ||||
| rated 3.8/6 overall mean score, showing the PicoSure to be as effective as the predicate device RevLite, rated 3.7/6 overall mean score. There | ||||
| were no deaths, serious adverse events (SAEs) or unanticipated adverse device effects (UADEs) reported in this study. The primary objectives of | ||||
| the study were to assess overall treatment efficacy through blinded photographic evaluation using a 6 point scale to grade improvement, assess | ||||
| safety of the PicoSure laser through the recording of side effects during the course of the study and compare efficacy of the PicoSure laser to the | ||||
| predicate device in a subset of patients, have been met. | ||||
| 807.92(b)(3) Conclusions drawn from clinical and non-clinical tests submitted | Testing confirmed that the PicoSure workstation with the 532 nm Laser Delivery System is safe and effective in the removal of tattoos. |
5-2